Table 2.

Overview of data submitted for subgroup 1.1.1 (IOFI, 2013)

Test substance	Test	Test conditions	Reference
Hex‐2(trans)‐enal [05.073] representative substance (purity: 98.2%)	Bacterial reverse mutation assay	Salmonella Typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 with and without metabolic activation up to 5,000 μg/plate	Sokolowski (2007a), Bhatia et al. (2010)
	In vivo micronucleus assay	Muta™mouse blood reticulocytes (days 1, 4 and 31) Treatment by oral gavage at doses of 120, 235 and 350 mg/kg bw per day for 28 days	Beevers (2013)
	Induction of lacZ‐mutations in Muta™Mouse	Muta™Mouse treatment by oral gavage at doses of 120, 235 and 350 mg/kg bw per day for 28 days. Mutation frequencies (day 31) determined in the liver and the duodenum	Beevers (2013)
	In vivo micronucleus assay	Treatment by oral route at doses of 250, 500, 1,000 mg/kg bw per day. Sampling of bone marrow was done 24 and 48 h after treatment	Honarvar (2007a)
	In vivo rat liver unscheduled DNA synthesis (UDS) assay	Treatment by oral route at doses of 200 and 500 mg/kg bw per day. Liver was perfused at 16 and 3 h after dosing	Durward (2009)
2‐Dodecenal [05.037] not representative (purity: 99.4%)	Bacterial reverse mutation assay	S. Typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 with and without metabolic activation up to 1,000 μg/plate	Sokolowski (2007b), Bhatia et al. (2010)
	In vivo micronucleus assay	Treatment by oral route at doses of 500, 1,000 and 2,000 mg/kg bw per day. Sampling of bone marrow was done 24 and 48 h after treatment. 2,000 PCE scored at 24 h (3 doses) and 48 h (top dose)	Honarvar (2007b), Bhatia et al. (2010)
2‐Nonenal [05.171] not representative (purity: 96.2%)	In vivo Micronucleus assay	Treatment by oral route at doses of 500, 1,000 and 2,000 mg/kg bw per day. Sampling of bone marrow was done 24 and 48 h after treatment. 2,000 PCE scored at 24 h (3 doses) and 48 h (top dose)	Honarvar (2008), Bhatia et al. (2010)

bw: body weight; PCE: polychromatic erythrocytes.